CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists.

With the approval of the first CAR T-cell products for hematological malignancies in 2017, these autologous cell therapies have changed the treatment paradigm for patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL), who have a poor prognosis and few effective treatment options. Despite the demonstrated clinical benefit in patients with r/r diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma, many patients who are eligible for CAR T-cell therapies do not receive them or are treated with CAR T cells as a later line of therapy at advanced stages of disease. Several barriers exist for referring patients to an authorized treatment center (ATC) for CAR T-cell therapy. Although most patients with NHL are treated by community-based oncologists, educational gaps may exist for some community oncologists about the availability of CAR T-cell therapies in certain indications, the overall treatment process, and how they can access these therapies for their patients. In addition to navigation of the referral process from the community setting to the ATC, other barriers include timely identification of candidates eligible for CAR T-cell therapy and logistical and reimbursement concerns. Here, we examine the patient CAR T-cell experience, which begins and ends in the community setting, and identify and discuss opportunities for improved collaboration between community oncologists and ATC physicians to help address barriers to treatment and enhance patient outcomes. Treatment decisions for a patient's second or third line of therapy for NHL are critically important, owing to declining probabilities for favorable outcomes with each successive line of therapy. For patients who are eligible, CAR T-cell therapies should be considered as early as possible in their treatment course. A better understanding of the CAR T-cell process, the patient's experience, and the collaboration necessary for timely patient identification, better access, and successful outcomes will enable more patients to benefit from CAR T-cell therapies.
Competing Interests: Declaration of competing interest M. R. Bishop has received consulting or advisory fees from Kite/Gilead, Novartis, Bristol Myers Squibb, CRISPR Therapeutics, Sana Therapeutics, Iovance, Servier, and In8Bio; has been paid to participate in a speakers’ bureau by Agios, Sanofi, Servier, Bristol Myers Squibb, and AstraZeneca; and has had travel expenses paid by Incyte and Sanofi. G. E. Kay has received consulting or advisory fees from Kite; has been paid to participate in a speakers’ bureau by Eli Lilly, Amgen, Sobi, and Seagen; and is an employee of and holds an ownership interest in Northwest Oncology.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)